 Approximately one in four prescription-only medicinal products are paid out of pocket by EU patients, whereas the rest is funded by the health care system or compulsory health insurances via reimbursement procedures. 1  For reimbursed products, the price setting process for new pharmaceutical products are clearly defined across EU markets with information being readily accessible.
Introduction

Results
Craddy P 1 , Bailey S 2 , Wolfram V 2 , Foxon G 2 1 Remap Consulting, Bern, Switzerland, 2 Remap Consulting, Cheshire, United Kingdom ISPOR 21 st Annual International Meeting, 21-15 May 2016, Washington, USA PHP55 National price submission procedures for non-reimbursed prescriptiononly medicinal products across 11 European countries  Price submission procedures were classified as: full price submission process; abridged price submission process, or no price submission ( Figure 2 ).  Nine of the 11 countries mandate submission of pricing documents (Table 1) .
• Six countries require a full price submission to the national pricing authority.
• Three countries ask for an abridged pricing submission (i.e. price notification).
• Two countries have no price submission or notification requirements.
 Negotiations with pricing bodies for non-reimbursed prescription-only products are limited, enabling manufacturers to have control over the price setting.
Methods
 To determine markets for inclusion within this study, Organisation for Economic Co-operation and Development (OECD) pharmaceutical spend data across Europe (based on 2012 [or latest available year]) was utilized to identify the countries that account for 90% of European pharmaceutical spend.
 Only countries covered by the centralized marketing authorisation procedure of the European Medicines Agency (EMA) were included in the analysis.
 11 countries, covered by the EMA, were found to represent 90% of European pharmaceutical spend.
 National price submission procedures for non-reimbursed prescription-only medicinal products across these 11 countries were analysed.
 Pricing authorities were contacted to obtain additional information related to price setting if ambiguities existed. 
Figure 1. Project process and outputs
Discussion and Conclusion
 The majority of countries require submission of pricing documents for nonreimbursed prescription-only medicinal products prior to product launch. As a result, the prices of these products are placed on official drug lists, which raises physician awareness of product availability.
 Typically, price submission processes are less burdensome for non-reimbursed products when compared to reimbursed products. Nevertheless, they are still time and resource intense to achieve a successful outcome.
 It is important for manufacturers to actively manage international prices, as several non-reimbursed markets require prices from other EU countries to be declared during the pricing process.
 With more freedom over prices manufacturers need to consider patient willingness to pay when determining the optimal non-reimbursed price levels.  Typically, time to patient access is faster for non-reimbursed prescription-only products compared to reimbursed products, but it is likely that the revenues will be lower, as patients may have lower willingness to pay.
 Whilst seeking a non-reimbursed launch price in Europe can be an optimal strategy for certain therapy areas, manufacturers should ensure such an approach optimizes revenues when compared to a reimbursed approach.
